TrumpRx: Side Effects Include Nausea, Vomiting, and a Net -24.
The drug-pricing program, meant to be a win, is pulling the administration below its own approval floor.
April 30, 2026 | 3 min read
Stop defending the price list. Start explaining why it exists. The moment voters hear Protonix costs $200 on TrumpRx and $14 at a retail pharmacy, the program is over. That comparison is already out there — and 52% of voters have already gone negative.
The TrumpRx drug-pricing program was supposed to be a healthcare populism play. The data says it’s becoming a liability that outpaces the president himself.
When voters were told that Senator Warren’s critique — that the heartburn drug Protonix is listed at$200 on TrumpRx versus $14 at a retail pharmacy — 52% oppose the program versus 28% who support it, a net -24 margin. For context, Trump’s own net approval in this survey sits at -12. TrumpRx is polling exactly twice as bad as the president. A program designed to showcase the administration’s healthcare credibility is instead functioning as a negative multiplier on it.
What makes this number harder to dismiss: 20% remain unsure, meaning roughly half of all voters have already gone negative before any sustained campaign-level messaging. This isn’t a finding that softens with more exposure — it’s a finding that hardens.
Kennedy Is the Wrong Messenger for This Fight
Robert F. Kennedy Jr.'s April 22 Senate Finance Committee appearance didn’t help. After being presented with details about his stated support for the measles vaccine alongside criticism of the budget cuts and TrumpRx, 48% oppose his HHS leadership versus 33% who support it — a net -15 margin. The 19% unsure is notable; Kennedy has more persuadable room than the program itself, which suggests his personal numbers aren’t locked in the way TrumpRx’s are.
But the deeper problem is structural.48% of voters say Kennedy’s management of HHS is a major issue in how they evaluate Trump’s job performance, versus 36% who call it minor. The healthcare portfolio isn’t siloed — it feeds directly into presidential approval. And the messenger running point on it is a known vaccine skeptic managing a department where 71% of voters favor requiring children to be vaccinated to attend public schools(34% strongly, 37% somewhat). Only 29% oppose. That’s the most lopsided policy finding in the entire survey.
We hadn’t fully anticipated the vaccine mandate number landing this cleanly. The assumption going in was that vaccine policy would be contested terrain. It isn’t. Seven in ten voters support the core public health infrastructure Kennedy has spent years casting doubt on — which means every time his skepticism resurfaces, he’s in direct conflict with a supermajority.
What the Price Comparison Is Actually Doing
The Protonix comparison ($200 vs. $14) is the kind of attack that works not because it’s complicated but because it’s concrete. Voters don’t need to understand drug-pricing mechanics. They understand that $200 is $186 more than $14. Awareness of Kennedy’s hearing was already at 58% pre-survey — higher than the budget vote-a-rama — and the 88% comprehension rate confirms the information is sticking. The clips are out there. They’re landing.
The question we’re still working through: is TrumpRx’s -24 driven by the specific price comparison, or is it absorbing broader anti-administration sentiment that would attach to any healthcare initiative right now? The attack vehicle is Elizabeth Warren’s framing — which means Republicans could argue this is a Democratic messaging artifact. We’re not sure that defense survives contact with a $186 price differential, but we’re watching.
What This Means in 30 Seconds
For campaigns: The Protonix number is a ready-made ad. $200 vs. $14 doesn’t need context — it is the context. Run it.
For lawmakers: A healthcare program polling at -24 while the president sits at -12 is not a program worth defending on the floor. Distance now, before the numbers compound.
For advocates: The 71% vaccine mandate support is a durable floor. Any Kennedy action that conflicts with school vaccination requirements will immediately activate a supermajority — and that’s a coalition worth holding together.
Methodology: Online survey of 519 likely voters fielded April 23, 2026, weighted by gender, race, education, 2024 presidential vote, birth year, and Trump approval. Respondents were also weighted by whether they passed attention checks. Margin of error: ±6.4%. AI-assisted drafting, human-verified analysis. Powered by the same tools we build for our clients.
Want the full crosstabs on TrumpRx by party and healthcare salience? Email data@tavernresearch.com →
